Frequency of use of thrombolytic therapy in acute myocardial infarction in Israel

Behar, Solomon; Abinader, Edward G.; Caspi, Avi; David, Daniel; Flieh, Michael; Friedman, Yaacov; Hod, Hanoch; Kaplinsky, Elieser; Kishon, Yehezkiel; Kristal, Natalio; Laniado, Shlomo; Markiewicz, Vladimier; Marmor, Alon; Palant, A; Pelled, B; Reisin, Leonardo; Rosenfeld, Tiberio; Roguin, N; Sherf, Libi; Rabinowitz, Babeth; Schlesinger, Z; Sclarovsky, Samuel; Zahavi, Izhar; Zion, Monty M.; Goldbourt, Uri

doi:10.1016/0002-9149(91)90233-b

Cited by 19 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is within the range (70-80%) suggested by Ketley and Woods10 11 as the likely optimum rate of eligibility for thrombolytic therapy and less than the National Health Service recommended rate (90%) 12. By contrast, some studies reporting low rates of thrombolytic use may have excluded potentially eligible patients—for example, elderly patients, diabetic patients, or patients treated by primary angioplasty 7 8…”

Section: Introductionmentioning

confidence: 59%

See 1 more Smart Citation

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

French

Williams

Hart

et al. 1996

BMJ

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 59%

“…The proportion of patients eligible for thrombolytic therapy reportedly varies from 15-16%7 8 to 79% 9. These figures are affected by whether eligibility is based on admission electrocardiographic and time window criteria or a discharge diagnosis of myocardial infarction.…”

Section: Introductionmentioning

confidence: 99%

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

French

Williams

Hart

et al. 1996

BMJ

View full text Add to dashboard Cite

“…T he outcome of patients with acute myocardial infarction (AMI) has been significantly improved during the last decade [6,19], mainly due to the extensive spread of aspirin ®, [3-blockers, and reperfusion therapy by pharmacological agents (that is thrombolytic therapy) and interventional catheterization methods [17]. However, 2 thirds of AMI-patients still do not receive lytic therapy [1,21] for a variety of reasons, and their mortality rate, especially in the elderly (> 70 years) is high, in the range of 12 to 25% [5,20,24].…”

Section: Discussionmentioning

confidence: 99%

Acute myocardial infarction without thrombolytic therapy: Beneficial effects of magnesium sulfate

Shechter

Hod

Chouraqui

et al. 1997

Herz

View full text Add to dashboard Cite

Only one third of hospitalized patients with acute myocardial infarction (AMI) receive thrombolytic therapy despite its proven benefits on outcomes. Elderly patients, have a greater risk of death during myocardial infarction; however, thrombolytic therapy appears to be less used in these patients, as compared to the general AMI-patients. In order to evaluate the impact of magnesium supplementation in AMI-patients without thrombolytic therapy, 194 patients participated in a prospective, randomized and placebo-controlled study: 96 patients received a 48-hour intravenous magnesium sulfate and 98 isotonic glucose as placebo. Magnesium infusion reduced the incidence of arrhythmias, congestive heart failure and in-hospital-mortality compared with placebo (27 vs. 40%, p = 0.04; 18 vs. 23%, p = 0.27; 4 vs. 17%, p < 0.01, respectively); in the subgroup of elderly patients (> 70 years), the benefit was also obvious (42 vs. 50%; 18 vs. 25%; 9 vs. 23%, p = 0.09, respectively). These data suggest that intravenous magnesium supplementation might be justified in order to reduce myocardial damage and mortality rate in subsets of high-risk patients such the elderly and/or patients not suitable for thrombolysis. Additional trials appear to be indicated to evaluate the potential benefit of magnesium in well defined specific subsets of AMT-patients.

show abstract

“…However, it is estimated that two thirds of AMI patients do not receive reperfusion therapy [2](i.e. thrombolytic agents or coronary angioplasty) and their in-hospital mortality rate, particularly in the elderly, is in the high range of 14–20% [3, 4, 5]. During the last decade, efforts have been made to find additional adjunctive pharmacologic treatments with the use of agents such as nitrates and angiotensin-converting enzyme inhibitors.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Outcome of Intravenous Magnesium Therapy in Thrombolysis-Ineligible Acute Myocardial Infarction Patients

Shechter

Hod²,

Rabinowitz³

et al. 2003

Cardiology

Self Cite

View full text Add to dashboard Cite

The aim of our study was to analyze the long-term survival and cardiac function in 194 consecutive, thrombolysis-ineligible acute myocardial infarction (AMI) patients receiving 48-hour intravenous magnesium sulfate (22 g) – 96 patients, compared with placebo – 98 patients. After a mean 4.8-year follow-up, all-cause mortality and cardiac mortality were significantly lower in the magnesium compared to the placebo group [(18 vs. 33 patients, p < 0.01) and (12 vs. 30 patients, p < 0.001), respectively]. Rest radionuclide ventriculography tests for left-ventricular ejection fraction (LVEF) were assessed in surviving patients up to completion of follow-up. Magnesium-treated patients had a significantly higher LVEF (0.51 ± 0.10 vs. 0.44 ± 0.14, p < 0.05) and a lower incidence of heart failure compared to placebo-treated patients (12 vs. 3 patients, p = 0.02). Beneficial effects of intravenous magnesium therapy in thrombolysis-ineligible AMI patients appeared to last for at least 4.8 years, concomitant with preserved LVEF, suggesting a favorable role for acute magnesium treatment in these patients.

show abstract

Frequency of use of thrombolytic therapy in acute myocardial infarction in Israel

Cited by 19 publications

References 10 publications

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

Acute myocardial infarction without thrombolytic therapy: Beneficial effects of magnesium sulfate

Long-Term Outcome of Intravenous Magnesium Therapy in Thrombolysis-Ineligible Acute Myocardial Infarction Patients

Contact Info

Product

Resources

About